Address: 4055 Oceanside BLVD,Oceanside, CA, 92056
Call us today: +1 442-224-3375
Validate your molecular targets using our available human models: primary cell lines, 3D cell cultures, precision-cut slices of human tissue, and a wide range of bio-banked disease-relevant patient materials.
Key benefits:
Screening of your library of tool compounds in a high-throughput fashion using established in our lab in vitro disease-relevant 3D human models.
A wide range of techniques used for the functional read-outs including protein analyte detection by Luminex, flow cytometric analysis, immunostaining, and more.
Characterization of the primary cancer cells
Drug efficacy and Mechanism-of-action analysis using 3D cancer models
Mainly used for scientific purposes at the stage of pre-clinical trials to identify drug efficiency.
Can become an innovative, reliable, and convenient tool for drug selection, which allows to choose the most effective drug for a particular type of tumor while minimizing side effects for the patient.
80% of the Phase 1 clinical studies fail in part because of the inadequacy of preclinical models, leading to costly failed studies and wasted effort.
DRL’s phase 0 clinical testing approach can de-risk phase 1 clinical studies by testing therapeutics in human patients. Our phase 0 trials are performed ethically and legally in certain patient indications (such as patients with brain death) whose organ systems involving absorption, metabolism, and excretion perform normally, allowing investigational drugs to be tested in a relevant clinical setting prior to phase 1 testing. DRL’s approach can assess dosages and side effects of therapeutics in a timely and robust manner.
We at DRL, along with the patients and families involved in the phase 0 studies, are motivated to accelerate the development of new therapeutics while preserving the lives of healthy people. Phase 0 patient participation is entirely voluntary, ethical, and performed in compliance with legal standards.
3D Organoids are miniature versions of tumor or organs that are robust representative models for R&D for use in target validation studies. DRL can identify and validate the expression of specific targets of interest in tumors or tissues of interest. By assessing the normal function of the target and its role in disease, we can accelerate the drug development process and ensure data can be translated into the in vivo (real world) setting.
Refer to the use of in vitro cell cultures grown in a flat, monolayer format on a solid surface, such as a petri dish or a microscope slide. These models are commonly used in the study of cell biology, pharmacology, and toxicology as they can be easily manipulated and analyzed using a variety of techniques.
Some examples of commonly used 2D cell line models include:
Fibroblast cell lines, such as NIH/3T3 cells, which are commonly used as a model for studying cell growth and differentiation
Epithelial cell lines, such as A431 cells, which are commonly used as a model for studying cell-cell interactions and the formation of tight junctions
Cancer cell lines, such as HeLa cells, which are commonly used as a model for studying the biology of cancer and the effects of chemotherapy drugs
While 2D cell line models have many advantages, they also have some limitations. For example, they do not accurately represent the three-dimensional (3D) architecture and microenvironment of tissues in vivo, which can lead to discrepancies in the results obtained from these models. Therefore, 3D cell culture models, such as organoids, have become increasingly popular in recent years.